# ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

> **NCT05507203** · PHASE3 · COMPLETED · sponsor: **Abivax S.A.** · enrollment: 639 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** ABX464
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05507203
- **Lead sponsor:** Abivax S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-10
- **Primary completion:** 2025-06-24
- **Final completion:** 2025-06-25
- **Target enrollment:** 639 (ACTUAL)
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05507203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05507203, "ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05507203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*